Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
:OTLK
Total Valuation
Outlook Therapeutics has a market cap or net worth of $109.72M. The enterprise value is $84.93M.
Market Cap$109.72M
Enterprise Value$84.93M
Share Statistics
Outlook Therapeutics has 44,419,530 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding44,419,530
Owned by Insiders31.77%
Owned by Institutions0.48%
Financial Efficiency
Outlook Therapeutics’s return on equity (ROE) is 1.03 and return on invested capital (ROIC) is -454.98%.
Return on Equity (ROE)1.03
Return on Assets (ROA)-2.61
Return on Invested Capital (ROIC)-454.98%
Return on Capital Employed (ROCE)5.22
Revenue Per Employee0.00
Profits Per Employee-3.28M
Employee Count23
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Outlook Therapeutics is ―. Outlook Therapeutics’s PEG ratio is 0.09.
PE Ratio―
PS Ratio0.00
PB Ratio-1.36
Price to Fair Value-1.36
Price to FCF-1.44
Price to Operating Cash Flow-0.82
PEG Ratio0.09
Income Statement
In the last 12 months, Outlook Therapeutics had revenue of 0.00 and earned -75.37M in profits. Earnings per share was -4.06.
Revenue0.00
Gross Profit-113.86K
Operating Income-71.70M
Pretax Income-75.36M
Net Income-75.37M
EBITDA-72.09M
Earnings Per Share (EPS)-4.06
Cash Flow
In the last 12 months, operating cash flow was -56.43M and capital expenditures 0.00, giving a free cash flow of -56.43M billion.
Operating Cash Flow-56.43M
Free Cash Flow-56.43M
Free Cash Flow per Share-1.27
Dividends & Yields
Outlook Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.69
52-Week Price Change62.14%
50-Day Moving Average1.60
200-Day Moving Average1.61
Relative Strength Index (RSI)64.50
Average Volume (3m)4.25M
Important Dates
Outlook Therapeutics upcoming earnings date is Feb 13, 2026, TBA (Confirmed).
Last Earnings DateDec 18, 2025
Next Earnings DateFeb 13, 2026
Ex-Dividend Date―
Financial Position
Outlook Therapeutics as a current ratio of 0.64, with Debt / Equity ratio of -93.30%
Current Ratio0.64
Quick Ratio0.64
Debt to Market Cap0.30
Net Debt to EBITDA-0.21
Interest Coverage Ratio-22.71
Taxes
In the past 12 months, Outlook Therapeutics has paid 2.80K in taxes.
Income Tax2.80K
Effective Tax Rate>-0.01
Enterprise Valuation
Outlook Therapeutics EV to EBITDA ratio is -1.58, with an EV/FCF ratio of -1.66.
EV to Sales0.00
EV to EBITDA-1.58
EV to Free Cash Flow-1.66
EV to Operating Cash Flow-1.66
Balance Sheet
Outlook Therapeutics has $8.90M in cash and marketable securities with $34.70M in debt, giving a net cash position of -$25.80M billion.
Cash & Marketable Securities$8.90M
Total Debt$34.70M
Net Cash-$25.80M
Net Cash Per Share-$0.58
Tangible Book Value Per Share-$3.94
Margins
Gross margin is 65.22%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin65.22%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Outlook Therapeutics is $4.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.50
Price Target Upside98.24% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast86.28%